Open AccessDesign, development, and characterization of amorphous rosuvastatin calcium tablets
Author(s) -
Rocío González,
María Ángeles Peña,
Norma Torres,
Antonio PeñaFernández
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0265263
Subject(s) - differential scanning calorimetry , friability , dissolution , materials science , amorphous solid , excipient , thermogravimetry , rosuvastatin calcium , active ingredient , dissolution testing , fourier transform infrared spectroscopy , chemical engineering , bioavailability , powder diffraction , chromatography , nuclear chemistry , chemistry , composite material , rosuvastatin , organic chemistry , polymer , crystallography , medicine , pharmacology , physics , biopharmaceutics classification system , ethyl cellulose , engineering , thermodynamics
This work proposes a methodology for the design, development, optimisation, and evaluation of amorphous rosuvastatin calcium tablets (BCS class II drug). The main goal was to ensure rapid disintegration and high dissolution rate of the active ingredient, thus enhancing its bioavailability. The design started from a careful selection of excipients, which due to their characteristics and proportions within the formulation allowed the use of their properties such as fluidity or granulometric distribution. The formulation was characterised using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), thermogravimetry (TGA), Fourier transform infrared spectroscopy (FT-IR) and powder X-ray diffraction (PXRD) methods. The galenic SeDeM methodology was used to establish the profile of the active ingredient-excipient mixture and guarantee its suitability for producing tablets by the direct compression method. The results demonstrate that the amorphous rosuvastatin calcium tablets formulation developed made it possible to obtain cost-effective tablets by direct compression with optimal pharmacotechnical characteristics that showed a remarkable disintegration and dissolution rate. The manufactured tablets complied with the pharmacopoeia guidelines regarding content uniformity, tablet hardness, thickness, friability, in vitro disintegration time and dissolution profile.